Yellow fever vaccine is a live, attenuated viral preparation from the 17D virus strain. Since 1996, 34 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been described. We report a new case of YEL-AVD. Given the potential risks associated with the vaccine, physicians should consider vaccination only for patients truly at risk for exposure to yellow fever, especially for primovaccination.
No takes yet. Share an insight, caveat, or question.
Muñóz et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: